We serve Chemical Name:[4-[5-[4-(dimethylamino)phenyl]-1,3-oxazol-2-yl]phenyl]boronic acid CAS:380499-66-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
![[4-[5-[4-(dimethylamino)phenyl]-1,3-oxazol-2-yl]phenyl]boronic acid](https://a.dearchem.com/CAS2/380499-66-1.png)
Chemical Name:[4-[5-[4-(dimethylamino)phenyl]-1,3-oxazol-2-yl]phenyl]boronic acid
CAS.NO:380499-66-1
Synonyms:or3311
Molecular Formula:C17H17BN2O3
Molecular Weight:308.13900
HS Code:2934999090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:544.2ºC at 760 mmHg
Density:1.28g/cm3
Index of Refraction:1.636
PSA:69.73000
Exact Mass:308.13300
LogP:1.75440
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like or3311 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,or3311 physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,or3311 Use and application,or3311 technical grade,usp/ep/jp grade.
Related News: Recipharm joined the COVID-19 fight in December, signing on to produce the Moderna vaccine at its plant in Monts, France. The company hasn’t revealed if the new facilities will be engaged in COVID-19 vaccine production, though the plant in Morocco will “mirror” a new fill-finish line it added in France. 3-bromo-5-iodo-2,4,6-trimethyl-pyridine manufacturers Wavelength, a more than 30-year-old firm based in Petah Tikva, launched its API CDMO business in early 2020 and currently sports more than 250 customers from 50 countries. 1H-Purin-2-amine, 6-[[4-(methylsulfonyl)-2-thienyl]methoxy]- suppliers The Plexxikon patents are for compounds that reduce cancer cell growth by blocking V600E mutated BRAF. Patents were filed as early as 2005. 11β-Hydroxy-12α-methylpregnan-3.20-dion vendor & factory Recipharm joined the COVID-19 fight in December, signing on to produce the Moderna vaccine at its plant in Monts, France. The company hasn’t revealed if the new facilities will be engaged in COVID-19 vaccine production, though the plant in Morocco will “mirror” a new fill-finish line it added in France.,“The Delta variant is clearly circulating, and it’s more contagious, and it seems to be causing more disease,” said ACIP member Katherine Poehling, M.D., an epidemiologist at Wake Forest School of Medicine.
